Title: Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: phase IIb clinical trial

Authors: María Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara; Juliet Enriquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos-Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang-Wu-Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel García-Rivera, Dagmar García-Rivera, Vicente Vérez-Bencomo and SOBERANA Research Group

Supplementary material

INDEX

Appendix A

A-1. Selection criteria for phase IIb clinical trial A-2. Outcomes.

Appendix B

Table 1. Summary of immunological variables evaluated in participants in the vaccine group, compared to participants in placebo group and the Cuban Convalescent Serum Panel (CCSP)

Table 2. Subgroup analysis of immunological variables in vaccine group after three doses

Table 3. Correlations between immunological variables after 2 and 3 doses in the vaccine group.

Table 4. Summary of immunological variables evaluated in individuals in the vaccine group 7-8 months after receiving the 3rd (heterologous) dose

Table 5. Global characterization of adverse events

Table 6. Frequency of subjects with adverse event by dose

Table 7. Unsolicited adverse events after any injection. Overall safety set

Table 8. Unsolicited serious and severe adverse events after any injection.

 Overall safety set

Table 9. Humoral immune response induced in subjects vaccinated with the heterologous schedule by batch of active pharmaceutical ingredient

 Table 10.
 Summary of adverse events by batch of active pharmaceutical ingredient

 Table 11. Frequency of subjects with adverse events by batch of active pharmaceutical ingredient

Figure 1. Solicited local and systemic events after each dose.

Figure 2. Risk-Benefit Balance.

Figure 3. Prediction of clinical efficacy from correlation between antibody responses and efficacy rate

Appendix C. Immunological Techniques

C.1 Anti-RBD IgG response

C.2 Molecular virus neutralization tests

C.5 Conventional virus neutralization test

Appendix A.

A1. Selection criteria for phase IIb clinical trial

Inclusion criteria:

- 1. Subjects who give written informed consent to participate in the study.
- 2. Subjects aged 19–59 years.

3. Women of childbearing potential, using safe contraceptive methods during the study.

4. Physical examination: normal or without clinically significant alterations.

Exclusion criteria:

1. Acute febrile or infectious disease in the 7 days prior to the administration of the vaccine or at the time of its application.

2. Antimicrobial treatment in the 7 days before the administration of the vaccine.

3. Poor weight (BMI <18.5) and obesity (BMI \ge 34.9).

4. Non-transmissible chronic diseases not controlled according to clinical or laboratory criteria (eg., bronchial asthma, chronic obstructive pulmonary disease, diabetes mellitus, thyroid diseases, ischemic heart disease, arterial hypertension, psychiatric disease, hemolymphopoietic disease).

5. Congenital or acquired immune system disease.

6. History of unresolved neoplastic disease.

7. History of liver or kidney failure.

8. History of substance abuse during the last 30 days or addictive illness to toxic substances, except if the subject is in abstinence, in the case of alcoholics, and smoking.

9. Diminished mental faculties for decision making.

10. History of severe allergic disease (anaphylactic shock, angioneurotic edema, glottis edema, severe urticaria).

11. History of hypersensitivity to thiomersal or to some of the components of the formulation.

12. History of SARS-CoV-2 and COVID-19 who meet any of the following criteria: a) Previous or current history of SARS-CoV-2 infection. b) Be declared in the category of contact or suspect at the time of inclusion. c) Subject with positive test for anti-SARS-CoV-2 antibodies. d) Subject with positive PCR at the time of inclusion.

13. Participation in another clinical trial in the last 3 months.

14. Application of vaccines containing tetanus toxoid in the last 3 months.

15. Application of other vaccines in the last 30 days.

16. Treatment with immunomodulators in the last 30 days, considering steroids (except topical and inhaled), cytostatics, interferon, immunoferon, transfer factor, monoclonal antibody, biomodulina T, any gammaglobulin, Levamisole, Heberferon, thymosin) or other drugs with immunomodulatory action. Persons requiring immunomodulatory treatment during the study.

17. Transfusion of blood or blood products in the last 3 months.

- 18. Subjects with difficulties in attending the planned follow-up consultations.
- 19. Splenectomy or splenic dysfunction.
- 20. Pregnancy, puerperium or breastfeed
- 21. Tattoos in the deltoid region on both arms.
- 22. Women with a positive pregnancy test.

A2- Outcomes.

Primary outcome(s):

 Anti-RBD IgG antibodies and percentage of subjects with seroconversion ≥4-fold the pre-vaccination level. Data collection: on days 0, 14, 42, 56, 70; 84.

Secondary outcomes for safety:

- 1) Solicited Local and systemic Adverse Events (AE);
 - a) Occurrence of the AE (Yes, No)
 - b) Duration (hours since the beginning until the end of the event)
 - c) Intensity of the AE (mild, moderate, severe)
 - d) Severe (serious, not serious)

e) Result (recovered, recovered with sequelae, persists, death, unknown) f) Causality (causal association consistent with vaccination, undetermined, causal association inconsistent with vaccination, not classifiable).

- Data collection: daily, for 7 days after each dose

- 2) Unsolicited Adverse Events (AE);
 - a) Description of the AE (name of the event)
 - b) Duration (hours since the beginning until the end of the event)
 - c) Intensity of the AE (mild, moderate, severe)
 - d) Severe (serious, not serious)
 - e) Result (recovered, recovered with sequelae, persists, death, unknown)

f) Causality (causal association consistent with vaccination, undetermined, causal association inconsistent with vaccination, not classifiable).
Data collection: daily, for 28 days after each dose

- 3) Serious Adverse Events (SAEs)
 - a) Occurrence of the SAE (Yes, No)
 - b) Duration (hours since the beginning until the end of the event)
 - c) Description of the event

d) Result (recovered, recovered with sequelae, persists, death, unknown)

e) Causality association (causal association consistent with vaccination, inconsistent causal association with vaccination, unclassifiable)

- Data collection: daily, for 28 days after each dose

Secondary outcomes for immunogenicity:

- 4) cVNT₅₀ (conventional live-virus neutralizing titer) Data collection: on days 0, 56, 70 and 84 (sample subset)
- 5) mVNT₅₀ (molecular virus neutralization titer) and % ACE2-RBD inhibition: Data collection: on days 0, 14, 42, 56, 70, 84.

Appendix B.

Table 1. Summary of immunological variables evaluated in participants in the vaccine group, compared to participants in placebo group and the Cuban Convalescent Serum Panel (CCSP)

				Vac	cine			Placebo		CCSP
		ТО	Post-1st dose T14	Post-2 nd dose T42	Post-2 nd dose T56	Post-3 rd dose T70-T80	Post-1st dose T14	Post-2 nd dose T42	Post-2 nd dose T56	
Anti-RBD IgG seroconversion	N (%)	-	72/350 (20.6)	251/343 (73.2)	522/684 (76.3)	635/656 (96.8)	2/52 (3.8)	0/46 (0.0)	7/96 (7.3)	-
	95% CI	-	(16.4; 25.2)*	(68.2; 77.8)*	(72.9; 79.4)*	(95.1; 98.0)*	(0.5; 13.2)	(0.00; 1.3)	(3.0; 14.4)	-
Anti-RBD IgG	Median	1.95	2.6	28.2	26.5	122.2	1.95	1.95	1.95	50.8
(AU/mL)	25 th -75 th	1.95; 1.95	1.95; 6.4*	7.4; 71.8*	9.0; 82.2*	47.2; 314.4*	1.95; 1.95	1.95; 1.95	1.95; 1.95	23.8; 94.0
RBD:hACE2	Median	7.0	6.3	26.1	28.4	85.5	2.7	3.7	2.8	32.0
INH%	25 th -75 th	0.4; 24.9	3.2; 15.0	9.4; 63.5*	10.8; 67.0*	49.4; 93.1*	0.5;	1.6; 7.4	0.3; 6.3	26.6; 62.2
mVNT ₅₀	GMT	-	-	59.2	62.5	289.0	-	-	13.2	41.8
	95% CI	-	-	50.5; 69.5*	55.9; 69.8*	258.4; 323.4*	-	-	11.8; 14.7	27.7; 63.2
cVNT ₅₀	GMT	0	-	-	65.9	219.6	-	-	-	46.4
	95% CI	0	-	-	46.9; 92.7	179.5; 268.8	-	-	-	31.5; 68.4

Footnote: Vaccine = Heterologous scheme: SOBERANA 02 (two doses, 28 days apart) + SOBERANA Plus. AU/mL = anti-RBD IgG concentration expressed in arbitrary units/mL. RBD:hACE2 INH% = RBD:hACE2 inhibition % at a dilution 1/100. mVNT₅₀ (molecular virus neutralization test) = serum dilution inhibiting 50% of RBD:hACE2 interaction. $cVNT_{50}$ = conventional live-virus neutralization titre. GMT = Geometric Mean Titre. 25th-75th=25-75 percentile. * p<0.005 versus placebo using chi-squared test (anti-RBD IgG seroconversion) Mann-Whitney U (anti-RBD IgG AU/mL, RBD:hACE2 INH%) or Student t test (mVNT₅₀, cVNT log-transformed). CCSP = Cuban Convalescent Serum Panel. No $cVNT_{50}$ was performed in samples from placebo as seroconversion was not detected in this group.

		Conventional viral neutralization (cVNT ₅₀)	Anti-RBD IgG concentration	Inhibition (%) of RBD:hACE2 interaction	Molecular virus neutralization (mVNT50)
	-	GMT (Cl 95%)	Median (25 th -75 th Percentile)	Median (25 th -75 th Percentile)	GMT (CI 95%)
	-	N=25	N=334	N=334	N=333
	F	198.7 (148.1; 266.5)	159.4 (60.2; 357.4)	89.6 (62.0; 93.7)	369.6 (317.2; 430.7)
Sov	М	N=16	N=322	N=322	N=320
Sex		256.9 (198.2; 333.2)	96.5 (37.6; 261.4)	79.7 (39.9; 91.6)	223.8 (190.6; 262.8)
	Mann- Whitney U	0.178*	0.000038	8.5e-7	0.00001*
	19-59 y/o	N=38	N=497	N=497	N=496
		229.4 (185.9; 282.9)	162.5 (62.1; 359.4)	88.5 (61.9; 93.5)	357.3 (316.5; 403.5)
Age	60-80 y/o	N=3	N=159	N=159	N=157
group		127.0 (47.0; 343.2)	53.5 (19.8; 141.1)	59.7 (29.5; 87.4)	147.9 (116.5; 187.8)
	Mann- Whitney U	0.125*	2.5e-14	3.4e-12	2.0e-11*
	Yes	N=6	N=225	N=225	N=224
		189.2 (96.0; 372.8)	78.6 (24.0; 252.5)	76.9 (33.0; 92.4)	202.1 (163.5; 187.8)
C	No	N=35	N=431	N=431	N=429
C		225.3 (180.6; 281.2)	160.1 (61.9; 351.9)	87.9 (62.0; 93.5)	348.4 (306.8; 395.8)
	Mann- Whitney U	0.544*	1.8e-7	0.000003	0.000018*

Table 2. Subgroup analysis of immunological variables in vaccine group after three doses

Footnote: C: comorbidities. * Student t test N: number of participants' sera evaluated.

			Anti-RBD	% Inh	mVNT ₅₀
			lgG (UA/mL)	RBD:hACE2	
After 2	Anti-RBD	r ² Spearman	1.000		
doses	lgG UA/mL	р	-		
		Ν	684		
	% Inh	r ² Spearman	0.918**	1.000	
	RBD:hACE2	р	0.000		
		Ν	681	681	
	mVNT ₅₀	r ² Spearman	0.899**	0.965**	1.000
		р	0.000	0.000	
		Ν	632	632	632
	cVNT ₅₀	r ² Spearman	0.598**	0.629**	0.632**
		р	0.000	0.000	0.000
		Ν	46	46	46
After 3	Anti-RBD	r ² Spearman	1.000		
doses	lgG UA/mL	р	-		
		Ν	656		
	% Inh	r ² Spearman	0.900**	1.000	
	RBD:hACE2	р	0.000		
		Ν	656	656	
	mVNT₅₀	r ² Spearman	0.909**	0.948**	1.000
		р	0.000	0.000	
		Ν	653	653	653
	cVNT ₅₀	r ² Spearman	0.787**	0.618**	0.729**
		р	0.000	0.000	0.000
		Ν	41	41	41

Table 3. Correlations between immunological variables after 2 and 3 doses in the vaccine group.

Footnote: ** p<0.01

			Vaccine		CCSP
		Post-2 nd dose T56	Post-3 rd dose T70-T80	7-8 months post 3 rd dose	•
Anti-RBD IgG	Ν	307	307	307	
seroconversion	N (%)	229 (74.6)	291 (94.8)	224 (73.0)	-
	95% CI	(69.3; 79.4)	(91.7; 97.0)*	(67.6; 77.8)	-
Anti-RBD IgG	Ν	307	307	307	68
(AU/mL)	Median	24.9	121.8	20.6	50.8
	25 th -75 th	8.2; 85.6*	44.5; 343.7*	6.9; 58.3	23.8; 94.0
mVNT ₅₀	Ν	261	261	261	68
	GMT	66.0	396.7	149.6	41.8
	95% CI	55.5; 78.5*	338.7; 464.6*	122.3; 182.9	27.7; 63.2

Table 4. Summary of immunological variables evaluated in individuals in the vaccine group 7-8 months after receiving the 3rd (heterologous) dose

Footnote: Vaccine = Heterologous scheme of SOBERANA 02 + SOBERANA Plus. AU/mL=anti-RBD IgG concentration expressed in arbitrary units/mL. mVNT50 = serum dilution inhibiting 50% of RBD:hACE2 interaction. GMT=Geometric Mean Titre. $25^{th}-75^{th}$ = 25-75 percentile. * p<0.005 versus 7-8 months using McNemar test (anti-RBD IgG titer Wilcoxon Signed Ranks test (anti-RBD IgG AU/mL) or Paired Student t test (mVNT₅₀, log-transformed). CCSP=Cuban Convalescent Serum Panel.

	Vaccine		Placebo		
		Frequency	%	Frequency	%
Total ad	verse events	899	100.0	48	100.0
	Mild (Grade 1)	831	92.4	46	95.8
	Moderate (Grade 2)	66	7.3	2	2.2
Intensity	Severe (Grade 3)	2	0.2	0	0.0
	lung and	pancreas neop pneu	olasm (1), monia (1)		
Severity	No Serious	892	99.2	47	97.9
Ceventy	Serious*	7	0.8	1	2.1
	Consistent (A1)	649	72.2	21	43.8
	Consistent (A2)	54	6.0	5	10.4
Causal	Consistent (A3)	3	0.3	0	0.0
relationship**	Indeterminate (B1)	16	1.8	2	4.2
	Indeterminate (B2)	3	0.3	0	0.0
	Inconsistent	175	19.5	20	41.7
	Recovered	890	99.0	48	100.0
	Recovered with sequels	1	0.3	0	0.0
Result			Swelling		
	Persist	8	0.9	0	0.0
	lung and pancreas neoplasm, diarrhea (2), myalgia, gallstones paint, glossitis, scabies. pneumonia				
Tumo	Local	583	64.8	12	25.0
туре	Systemic	316	35.2	36	75.0
Solicitod	Solicited	614	68.3	16	33.3
Solicited	Unsolicited	285	31.7	32	66.7
	≤ 60 min	45	5.0	4	8.3
	60 min-24 hours	516	57.4	21	43.8
Starting at	24-48 hours	223	24.8	12	25.0
	48-72 hours	61	6.8	6	12.5
	> 72 hours	54	6.0	5	10.4
	≤ 24 hours	608	67.6	35	72.9
	24-48 hours	150	16.7	4	8.3
Duration (hours)	48-72 hours	74	8.2	1	2.1
	> 72 hours	53	5.9	7	14.6
	Unspecified	14	1.6	1	2.1

Table 5. Global characterization of adverse events

Footnote: Frequency: number of events, %: values referred to total events. * In Vaccine group: Consistent to conditions inherent to the vaccinated (multiform erythema); Inconsistent

(pulmonary neoplasm, pneumonia, diarrhea, lipothymia, rectal bleeding, atrial fibrillation). In placebo group: Inconsistent (megaloblastic anemia).

** A1: Vaccine-related event (according to published literature); A2: Event related to a defect in the quality of the vaccine; A3: Event related to a programmatic / technical error; A4: Event related to the conditions inherent to the vaccinated subject; B1: The temporal relationship is consistent, but the evidence is insufficient to consider the vaccination as cause of the event; B2: Classification criteria result in contradiction regarding consistencies and inconsistencies with a causal association with immunization.

	Any adverse event		
	Vaccine	Placebo	
	Frequency (%)	Frequency (%)	
N	758	102	
Overall adverse events wi	thin 28 days after vaccina	ation	
Subject with AE	352 (46.4)	24 (23.5)	
1 st dose	312/758 (41.2)	21/102 (20.6)	
2 nd dose	169/743 (22.7)	8/97 (8.2)	
3 rd dose	64/732 (8.7)		
Subjects with solicited ad	verse events within 7 day	ys after vaccination	
Any	343 (45.3)	22 (21.6)	
1 st dose	305/758 (40.2)	18/102 (17.6)	
2 nd dose	164/743 (22.1)	8/97 (8.2)	
3 rd dose	64/732 (8.7)		
Subjects with solicited sy	stemic adverse events	-	
Any	35 (4.6)	3 (2.9)	
1 st dose	20/758 (2.6)	1/102 (1.0)	
2 nd dose	12/743 (1.6)	2/97 (2.1)	
3 rd dose	7/732 (1.0)		
General discomfort	32 (4.2)	3 (2.9)	
1 st dose	19/758 (2.6)	1/102 (1.0)	
2 nd dose	10/743 (1.3)	2/97 (2.1)	
3 rd dose	7/732 (1.0)		
Rash	1 (0.1)	0	
1 st dose	1/758 (0.1)	0	
2 nd dose	0	0	
3 rd dose	0		
Fever	2 (0.3)	1 (1.0)	
1 st dose	0	0	
2 nd dose	1/743 (0.1)	1/97 (1.0)	
3 rd dose	1/732 (0.1)		
Mild fever	1 (0.1)	0	
1 st dose	0	0	
2 nd dose	1/743 (0.1)	0	
3 rd dose	0		
Subjects with solicited loo	cal adverse events	-	
Any	294 (38.8)	11 (10.8)	
1 st dose	245/758 (32.3)	9/102 (8.8)	
2 nd dose	150/743 (20.2)	2/97 (2.1)	
3 rd dose	51/732 (7.0)		
Injection-site pain	263 (34.7)	9 (8.8)	
1 st dose	223/758 (29.4)	7/102 (6.9)	
2 nd dose	131/743 (17.6)	2/97 (2.1)	
3 rd dose	24/732 (3.3)		
Frythema	13 (1 7)	0 (0 0)	

Table 6. Frequency of subjects with adverse event by dose

	Any adverse event		
	Vaccine Frequency (%)	Placebo Frequency (%)	
N	758	102	
1 st dose	7/758 (0.9)	0	
2 nd dose	2/743 (0.3)	0	
3 rd dose	4/732 (0.5)		
Local Warm	44 (5.8)	2 (2.1)	
1 st dose	24/758 (3.2)	2 (2.1)	
2 nd dose	11/743 (1.5)	0	
3 rd dose	12/732 (1.6)		
Induration	37 (4.9)	0 (0.0)	
1 st dose	22/758 (2.9)	0	
2 nd dose	13/743 (1.7)	0	
3 rd dose	6/732 (0.8)		
Swelling	93 (12.3)	0 (0.0)	
1 st dose	51/758 (6.7)	0	
2 nd dose	32/743 (4.3)	0	
3 rd dose	27/732 (3.7)		

Table 7. Unsolicited adverse events after any injection. Overall safety set

	Vaccine Frequency (%)	Placebo Frequency (%)
Ν	708	102
Number of participants reporting unsolicited AEs	159 (22.5)	19 (18.6)
Vaccine-related	72 (10.2)*	7 (6.9)**
Hypertension	27 (3.8)	3 (2.9)
Headache	39 (5.5)	2 (2.0)
Non Vaccine-related	114 (16.1)***	15 (14.7)****
Hypertension	7 (1.0)	1 (1.0)
Headache	18 (2.5)	1 (1.0)
Upper Acute respiratory infection	14 (2.0)	3 (2.9)
Diarrhea	17 (2.4)	0
Myalgia	18 (2.5)	1 (1.0)
Abdominal pain	11 (1.6)	1 (1.0)

Footnote: * Reported by 1 subject (0.1%, each one): burning, asthenia, nasal secretion, diarrhea, precordial pain, multiform erythema, chills, general discomfort, dizziness, myalgia, migraine, nausea, toothache, paresthesia in upper limb, blush, drowsiness, tachycardia, cough, vertigo, vomiting; local hematoma (3 subjects: 0.4%).

** Reported by 1 subject (1%, each one): general discomfort, palpitations

****Reporting for 1 subject (1%, each one): submaxilar adenitis, megaloblastic anemia, sinus bradycardia, cellulite in sacral region, conjunctivitis, atopic dermatitis, pharyngeal itching, dizziness, migraine, otalgia palpitations, blush, drowsiness

^{***} Reported by < 1%: dental abscess, oral thrush, food allergy, anxiety, burning when urinating, asthenia, volume increase in the abdominal region, sinus bradycardia, cellulite in hand and arm, conjunctivitis, nasal secretion, atopic dermatitis, pain by vesicular lithiasis, precordial pain, chest pain, edema in lower limbs, bilateral epicondylitis, scabies, chills, pharyngeal burning, allergic pharingitis, atrial fibrillation, knee forunculus, glositis, stocks with blood, hydroadenitis, acute ingestion, acute lymphangitis in lower member, lipotimia, general discomfort, eye disorder, dizziness, migraine, nausea, lung and pancreas neoplasm, pneumonia, ,tooth pain, osteocondritis, paresthesia, paresthesia in upper limb, paronychia, insect bite pain, polaquyuria, itching in upper limb, generalized itching, local itching, allergic rhinitis, blush, salpingitis, rectal bleeding, urinary sepsis, vagal syndrome, drowsiness, stiff neck, cough, vertigo, vomiting.

**** Reporting for 1 subject (1%, each one): Submaxilar adenitis, Megaloblastic anemia, Sinus bradycardia, Cellulite in sacral region, Conjunctivitis, Atopic dermatitis, Pharyngeal itching, Dizziness, Migraine, Otalgia Palpitations, Blush, Drowsiness

 Table 8. Unsolicited serious and severe adverse events after any injection.

 Overall safety set

	Vaccine	Placebo
	708	102
Number of participants reporting unsolicited AEs	159 (22.5)	19 (18.6)
Number of participants reporting unsolicited Serious AEs	4 (0.6%)	1 (1.0%)
Vaccine-related	1 (0.1)	0
Multiform erythema	1 (0.1)	0
Non Vaccine-related	3 (0.4)	1 (1.0)
Atrial fibrillation	1 (0.1)	0
Lung and pancreas neoplasm ^{S1}	1 (0.1)	0
Pneumonia ^{s1}	1 (0.1)	0
Lipothymia ^{S2}	1 (0.1)	0
Rectal bleeding ^{S2}	1 (0.1)	0
Diarrhea ^{S2}	1 (0.1)	0
Megaloblastic anemia	0	1 (1.0)
Number of participants reporting unsolicited Severe AEs	1 (0.1)	0
Non Vaccine-related	1 (0.1)	0
Lung and pancreas neoplasm ^{S1}	1 (0.1)	0
Pneumonia ^{s1}	1 (0.1)	0

Footnote: ^{S1}: In the same subject; ^{S2}: In the same subject

Table 9. Humoral immune response induced in subjects vaccinated with the heterologous schedule by batch of active pharmaceutical ingredient

		API	Batch-1	API B	atch-2
		Post-2 nd dose T56	Post-3 rd dose T70-T80	Post-2 nd dose T56	Post-3 rd dose T70-T80
Anti-RBD IgG	N (%)	265/341 (77.7)	307/318 (96.5)	257/343 (74.9)	328/338 (97.0)
seroconversion	95% CI	(72.9; 82.0)	(93.9; 98.3)	(70.0; 79.4)	(94.6; 98.6)
Anti-RBD IgG	Median	32.7	121.9	22.5	128.4
(AU/mL)	25 th -75 th	10.1; 98.6	45.3; 328.4	8.1; 63.5	48.9; 311.4
RBD:hACE2 INH%	Median	35.2	84.7	24.2	86.4
	25 th -75 th	11.2; 71.6	45.1; 92.9	10.4; 58.0	52.2; 93.2
mVNT ₅₀	GMT	70.2	275.1	55.4	302.7
	95% CI	59.8; 82.4	232.5; 325.4	47.6; 64.5	260.5; 351.8
cVNT ₅₀	GMT	69.9	201.8	61.9	242.4
	95% CI	42.9; 113.7	153.4; 265.3	36.9; 103.8	175.7; 334.2

Footnote: API: Active Pharmaceutical Ingredient, AU/mL=anti-RBD IgG concentration expressed in arbitrary units/mL. RBD:hACE2 INH%= RBD:hACE2 inhibition % at a dilution 1/100. mVNT₅₀=serum dilution inhibiting 50% of RBD:hACE2 interaction. cVNT₅₀=conventional live-virus neutralization titer. GMT=Geometric Mean Titre. 25th-75th=25-75 percentile. CI=confidence interval

	API Batch-1	API Batch-2
N (%)	354 (100.0)	354 (100.0)
Subjects with some AE	164 (46.3)	172 (48.6)
Subjects with some VAAE	157 (44.4)	154 (43.5)
Subjects with some Serious AE	2 (0.6)	2 (0.6)
Subjects with some Serious VAAE	1 (0.3)	0 (0.0)
Subjects with some Severe AE (no VAAE)	1 (0.3)	0 (0.0)
Total Adverse Events	429 (100)	470 (100)
VAAE	339 (79.0)	367 (78.1)
Serious AE	3 (0.7)	4 (0.9)
Serious VAAE	1 (0.2)	0 (0.0)
Severe AE(no VAAE)	2 (0.5)	0 (0.0)

Table 10. Summary of adverse events by batch of active pharmaceutical ingredient

Footnote: API: Active Pharmaceutical Ingredient, VAAE: Vaccine-Associated Adverse Event

 Table 11
 Frequency of subjects with adverse events by batch of active pharmaceutical ingredient

			API Batch-1	API Batch-2
Total (%)			354 (100.0)	354 (100.0)
Subjects wit	h some AE		164 (46.3)	172 (48.6)
Solicited	Local	Injection-site pain	123 (34.7)	128 (36.2)
		Swelling	46 (13.0)	46 (13.0)
		Local warm	21 (5.9)	22 (6.2)
		Induration	16 (4.5)	20 (5.6)
		Erythema	6 (1.7)	7 (2.0)
	Systemic	General discomfort	18 (5.1)	11 (3.1)
		Fever	1 (0.3)	1 (0.3)
		Rash	1 (0.3)	0 (0.0)
		Mild fever	0 (0.0)	1 (0.3)
	Local	Local Hematoma	3 (0.8)	0 (0)
		Local Itching	1 (0.3)	0 (0)
		Burning	1 (0.3)	0 (0)
Unsolicited		Cellulite of the hand and arm	1 (0.3)	0 (0)
	Systemic	Headache	26 (7.3)	26 (7.3)
		Hypertension	13 (3.7)	18 (5.1)
		Diarrhea	7 (2.0)	11 (3.1)

		API Batch-1	API Batch-2
Total (%)		354 (100.0)	354 (100.0)
	Cough	2 (0.6)	4 (1.1)
	Asthenia	3 (0.8)	2 (0.6)
	Nausea	4 (1.1)	1 (0.3)
	Upper Acute respiratory infection	5 (1.4)	9 (2.5)
	Allergic rhinitis	1 (0.3)	4 (1.1)
	Migraine	3 (0.8)	0 (0)
	Drowsiness	2 (0.6)	0 (0.0)
	Nasal secretion	1 (0.3)	3 (0.8)
	Dizziness	1 (0.3)	2 (0.6)
	Abdominal pain	5 (1.4)	6 (1.7)
	General discomfort	1 (0.3)	1 (0.3)
	Vertigo	1 (0.3)	2 (0.6)
	Atopic dermatitis	1 (0.3)	3 (0.8)
	Sinus bradycardia	0 (0.0)	2 (0.6)
	Pharyngeal burning	0 (0.0)	1 (0.3)
	Toothache	2 (0.5)	0 (0.0)
	Paraesthesia	1 (0.3)	0 (0.0)
	Vomiting	2 (0.6)	0 (0.0)
	Food Allergy	1 (0.3)	1 (0.3)
	Chest pain	1 (0.3)	1 (0.3)
	Chills	1 (0.3)	1 (0.3)
	Pharyngitis	1 (0.3)	1 (0.3)
	Acute ingestion	1 (0.3)	1 (0.3)
	Generalized itching	1 (0.3)	2 (0.6)
	Blush	1 (0.3)	1 (0.3)
	Vagal syndrome	0 (0.0)	2 (0.6)
	Anxiety	1 (0.3)	0 (0.0)
	Volume increase in the abdominal region	1 (0.3)	0 (0.0)
	Insect bite pain	1 (0.3)	0 (0.0)
	Edema in lower limbs	1 (0.3)	0 (0.0)
	Bilateral epicondylitis	1 (0.3)	0 (0.0)
	Multiform erythema	1 (0.3)	0 (0.0)
	Glossitis	1 (0.3)	0 (0.0)
	Hydroadenitis	1 (0.3)	0 (0.0)
	Conjunctivitis	2 (0.6)	1 (0.3)
	Acute lower limb lymphangitis	1 (0.3)	0 (0.0)

		API Batch-1	API Batch-2
Total (%)		354 (100.0)	354 (100.0)
	Pain by vesicular lithiasis	1 (0.3)	0 (0.0)
	Chest pain	1 (0.3)	1 (0.3)
	Eye discomfort	1 (0.3)	0 (0.0)
	Lung and pancreas neoplasm	1 (0.3)	0 (0.0)
	Upper limb paresthesia	2 (0.6)	2 (0.6)
	Dental abscess	0 (0.0)	1 (0.3)
	Oral thrush	0 (0.0)	1 (0.3)
	Burning when urinating	0 (0.0)	1 (0.3)
	Scabies	0 (0.0)	1 (0.3)
	Acute atrial fibrillation	0 (0.0)	1 (0.3)
	Right knee furuncle	0 (0.0)	1 (0.3)
	Bloody stools	0 (0.0)	1 (0.3)
	Lipothymia	0 (0.0)	1 (0.3)
	Myalgia	10 (2.8)	9 (2.5)
	Pneumonia	1 (0.3)	1 (0.3)
	Osteochondritis	0 (0.0)	1 (0.3)
	Paronychia	0 (0.0)	1 (0.3)
	Polaquyuria	0 (0.0)	1 (0.3)
	Itching in upper limb	0 (0.0)	2 (0.6)
	Salpingitis	0 (0.0)	1 (0.3)
	Rectal bleeding	0 (0.0)	1 (0.3)
	Tachycardia	0 (0.0)	1 (0.3)
	Stiff neck	0 (0.0)	1 (0.3)

Footnote: API: Active Pharmaceutical Ingredient





Figure 1. Solicited local and systemic events after each dose.

Footnote: Subjects received two doses (on days T0, T28) of SOBERANA 02 (FR-2) or Placebo (Pb) and a third dose (on day T56) of SOBERANA Plus.





Footnote: Benefit₁ = Proportion of individuals with seroconversion (\geq 4-fold increase in antibody concentration over pre-immunization levels) on day 84. Risk₁ = Serious vaccine-related adverse events.



Figure 3. Prediction of clinical efficacy from correlation between antibody responses and efficacy rate

Footnote: Panels A and B display correlations of antibody responses for IgG and neutralization and assay ratios, respectively for eight vaccines. The y-axis is estimated log risk ratio reported on the vaccine efficacy scale. The x-axis is log ratio of the peak geometric mean neutralization titer or ELISA titer at 7-28 days post-vaccination, relative to HCS (except for Oxford/AZ and SOBERANA antibody responses, which represent ratios of median titers). Prediction values for SOBERANA were estimated using a regression linear model

Appendix C. Immunological Techniques

C.1 Anti-RBD IgG response: Anti-RBD IgG in sera was evaluated by a quantitative ultramicro ELISA (UMELISA SARS-CoV-2 anti- RBD, Center for Immunoassay, Havana, Cuba) using d-RBD as coating antigen (4 µg/mL) and an in-house standard- characterized serum, which was arbitrarily assigned 200 AU/mL (based on a half-maximal inhibitory titer of 200 and a conventional virus neutralization titer of 160). The standard curve comprised six two-fold serial dilutions (0, 4, 8, 16, 32 and 64 AU/mL) of the standard. Samples were evaluated in duplicate. After incubation step, biotin-conjugate anti-IgG human (0.1 µg/mL) (Sigma Aldrich, San Luis, EE UU) and later, streptavidin/alkaline-phosphatase Roche, Basel, Swiss) in appropriate buffers were added. The final fluorimetric reaction was induced by adding the substrate 4-methylumbelliferyl phosphate (Sigma Aldrich, San Luis, EE UU). The reference curve was constructed using a linear interpolation function. The concentration of anti-RBD IgG was expressed as AU/mL. The seroconversion rate was calculated by dividing the concentration at each time point (at Tx) by the pre-vaccination concentration (at T0). A rate ≥ 4 was considered as seroconversion.

C.2 Molecular viral neutralization test

This ELISA is an *in-vitro* surrogate of the life-virus neutralization [i]. It uses recombinant RBD-mouse-Fc (RBD-Fcm) and the host cell receptor hACE2-Fc (ACE2-Fch) as coating antigen. Human antibodies against RBD can block the RBD-Fcm interaction with ACE2-Fch. The RBD-Fcm that was not inhibited can bind to ACE2-Fch, and is recognized by a monoclonal antibody anti- γ murine conjugated to alkaline phosphatase. The results are expressed as % inhibition of RBD-hACE2 interaction (at a serum dilution of 1/100); and as the half molecular virus neutralization titre (mVNT₅₀) represented as the maximal serum dilution inhibiting 50% of RBD-hACE2 interaction

C.3 Conventional Viral neutralization test

Neutralizing antibodies against live SARS-CoV-2 was performed in a biosecurity laboratory level 3 (National Civil Defence Research Laboratory, Havana, Cuba) by the conventional virus neutralization test, the gold standard for determining antibody efficacy against SARS-CoV-2, following the recommendation of Manenti & cols [ii]. Serial dilutions of heat-inactivated serum samples (starting from 1:5) in Eagle's Minimal Essential Medium (Gibco, UK) containing 2 % fetal bovine serum (Capricorn, Germany) were incubated for 1 hour at 37°C with an equal volume of viral solution containing 100 TCID₅₀ of SARS-CoV-2 (strains: CU2010-2025, variant D614G; CU2101-2102, variant B.1.1.7 alpha; CU2104-2179, variant B.1.617.2 delta; CU2104-2180, variant B.1.351 beta; Cuban Collection at the National Civil Defence Research Laboratory) in cell plates containing a semiconfluent Vero E6 monolayer (10⁴ cell/well). The highest serum dilution showing an OD at 540 nm, representing the 50% of average OD values from control cell wells (Vero E6 monolayer with mixture of virus-serum) was considered as the neutralization titre and is represented as neutralizing titre 50 (cVNT₅₀).

ⁱⁱ Manenti A, Maggetti M, Casa E, et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol. 2020; 92(10): 2096-104. <u>https://doi.org/10.1002/jmv.25986</u>

ⁱ Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38:1073-8. <u>https://doi.org/10.1038/s41587-020-0631-z</u>